SCHEMBL4840530

SCHEMBL4840530

COc1ccc(N(C(=O)Nc2cccc(C)c2)c2ccnc(NC(C)C(C)(C)O)n2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.73
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
TP53 P04637 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDR P35968 2/20 0.40
LCK P06239 1/20 0.40
SRC P12931 1/20 0.40
PDGFRA P16234 1/20 0.39
USP2 O75604 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KCNK3 O14649 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4840534 1.00 MAPK14 (0.73) MAPK14NPC1RAB9ATP53NFKB1
SCHEMBL4836187 0.91 MAPK14 (0.73) MAPK14NPC1RAB9ASMN1; SMN2KDR
SCHEMBL4840138 0.91 MAPK14 (0.70) MAPK14NPC1RAB9ATP53SMN1; SMN2
SCHEMBL4836181 0.91 MAPK14 (0.73) MAPK14NPC1RAB9ASMN1; SMN2KDR
SCHEMBL4840147 0.91 MAPK14 (0.70) MAPK14NPC1RAB9ATP53SMN1; SMN2
SCHEMBL4828877 0.90 MAPK14 (0.68) MAPK14NPC1RAB9AKDRSRC
SCHEMBL4828889 0.90 MAPK14 (0.68) MAPK14NPC1RAB9AKDRSRC
SCHEMBL4835627 0.90 MAPK14 (0.72) MAPK14NPC1RAB9ASMN1; SMN2KDR
SCHEMBL4835636 0.90 MAPK14 (0.72) MAPK14NPC1RAB9ASMN1; SMN2KDR
SCHEMBL4839045 0.90 MAPK14 (0.75) MAPK14NPC1RAB9ATP53KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7402589-B2 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-07-22 US claimed
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-11-03 US claimed
US-7402589-B2 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-07-22 US disclosed
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors IL1B, IL1A, IL6 MAPK14 2674/4885NPC1 3402/4885RAB9A 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.